For example, combination of MEK inhibitors with ErbB inhibitors is effective in epithelial NSCLC cells, whereas in mesenchymal cells pathway reactivation is blocked with FGFR inhibitors [62]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.